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Asthma is a highly complex disease that is still poorly
understood and whose cause remains unknown. One of
the striking advances in the last decade has been the
recognition that cytokines play a critical role in orchestrat-
ing, perpetuating and amplifying the inflammatory
response in asthma. Indeed the increased and abnormal
expression of cytokines in airway cells is one of the major
targets of corticosteroid therapy, by far the most effective
controller treatment for asthma currently available. Many
cytokines and chemokines are involved in the pathophysi-
ology of asthma [1,2]. While some of these cytokines,
such as interleukin (IL)-1, tumour necrosis factor-a and
IL-6, are involved in many inflammatory diseases, including
chronic obstructive pulmonary disease, rheumatoid arthri-
tis and inflammatory bowel disease, others are more spe-
cific to allergic inflammation. These cytokines, IL-4, IL-5,
IL-9 and IL-13, are derived from T helper type 2 (Th2)
cells, although they may also derive from other cell types.
Th2 cells are recognised by their secretion of IL-4, IL-5,
IL-9 and IL-13, as opposed to Th1 cells, which secrete
IL-2 and interferon-g, although the clear distinction
between Th1 and Th2 cells is not as distinct in humans as
in mice. Th2 cytokines may play an important role in the
pathophysiology of allergic diseases, including asthma.
They may be useful therapeutic targets in the future man-
agement of allergic diseases, and several approaches to
inhibiting these cytokines are now being tested in clinical
trials or are in active development [3].
In this issue of Respiratory Research we focus on Th2
cytokines and their potential role in allergic diseases, such
as asthma. John Steinke and Larry Borish [4] discuss the
role of IL-4 in the pathogenesis of asthma and make the
point that this is an upstream cytokine that regulates aller-
gic inflammation by promoting Th2 cell differentiation and
IgE synthesis. Early studies with an IL-4 antagonist,
soluble recombinant IL-4 receptor (altrakincept), show
therapeutic benefit as a steroid-replacing agent in moder-
ately severe asthma [5] and longer term clinical trials are
now underway. IL-5 is discussed by Scott Greenfeder and
colleagues [6]. IL-5 is a cytokine that is highly specific for
eosinophilic inflammation and antibodies that block IL-5
actions are effective in reducing eosinophilic inflammation
and airway hyperresponsiveness (AHR) in various species.
Recently, studies of a humanised anti-IL-5 monoclonal
antibody (mepomizulab) in asthmatic patients have con-
firmed its extraordinary efficacy in reducing eosinophils in
the circulation and the airways, but surprisingly no reduc-
tion in response to allergen or in AHR [7]. This result has
been confirmed in a preliminary clinical trial of asthmatic
patients whose symptoms were not controlled with
inhaled corticosteroids and who showed no clinical
improvement with anti-IL-5 antibody, despite a marked
suppression of circulating eosinophils [8]. These studies
confirm the importance of IL-5 in eosinophilic inflammation
in man, but question the role of eosinophils in asthma.
IL-13 has many actions similar to those of IL-4 and also
regulates IgE production but, unlike IL-4, it does not regu-
late T cell differentiation to Th2 cells and T lymphocytes
do not respond to IL-13. The role of IL-13 in asthma was
recently reviewed in this journal by Marsha Wills-Carp [9].
IL-9 has been less intensively investigated than the other
Th2 cytokines, but appears to amplify Th2-cell-mediated
responses, as reviewed by Roy Levitt and colleagues in
this issue [10]. They make a persuasive case for this
cytokine as a target for inhibition in asthma.
The reason why Th2 cells should be more prominent in
allergic diseases such as asthma is still unknown but the
hygiene hypothesis is a persuasive theory, suggesting that
lack of infection and exposure to endotoxins in dirt may
alter the balance between Th1 and Th2 cells. This hypothe-
sis now has increasing support from experimental animals
and from epidemiological studies, as will be discussed by
Fernando Martinez in the next issue of Respiratory
Research. This has important therapeutic implications and
suggests that stimulating Th1 cells might suppress Th2
cells and allergic inflammation. Genetic polymorphisms
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may be one of the factors predisposing to the imbalance
between Th1 and Th2 cells, including single nucleotide
polymorphisms (SNPs) of the endotoxin receptor CD14.
SNPs and predisposition to asthma are also discussed in
this issue of Respiratory Research by Lyle Palmer and Bill
Cookson [11], and several SNPs of the genes encoding
Th2 cytokines (which are situated together in a cluster on
chromosome 5q) and their receptors have now been
associated with increased risk of atopy and asthma.
We live in exciting times, when the availability of new mol-
ecular and genetic techniques is beginning to elucidate
some of the complexities of asthma. It is likely that this will
lead to even more effective and specific therapies in the
future that may be targeted to individual patients. The
prospect of a cure for asthma is coming closer.
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